65 filings
8-K
JNCE
Jounce Therapeutics Inc
4 May 23
Termination of a Material Definitive Agreement
7:22am
8-K
JNCE
Jounce Therapeutics Inc
30 Mar 23
Departure of Directors or Certain Officers
4:08pm
8-K
JNCE
Jounce Therapeutics Inc
27 Mar 23
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
9:02am
8-K
JNCE
Jounce Therapeutics Inc
15 Mar 23
Other Events
6:21am
8-K
JNCE
Jounce Therapeutics Inc
13 Mar 23
Regulation FD Disclosure
6:30am
8-K
341e77wa97 7j3
23 Feb 23
Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking
6:11am
8-K
occro26m lc
20 Jan 23
Departure of Directors or Certain Officers
8:07am
8-K
0m0ic
5 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
9uanp k9gvfc39dv
27 Dec 22
Entry into a Material Definitive Agreement
4:31pm
8-K
h5rrpsmz hr99y
20 Dec 22
Departure of Directors or Certain Officers
7:21am
8-K
e3123yoxing715wzy9qs
10 Nov 22
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
7:17am
8-K
wk2hic4329f
30 Aug 22
Regulation FD Disclosure
8:07am
8-K
66hnwd697cq8l4t
4 Aug 22
Jounce Therapeutics Reports Second Quarter 2022 Financial Results
7:13am
8-K
kb98poyarijqvyhhufi
27 Jun 22
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
ojrw2bqwg5cr6p3
5 May 22
Jounce Therapeutics Reports First Quarter 2022 Financial Results
7:07am
8-K
efjms 0o38dtqau
7 Mar 22
Regulation FD Disclosure
7:06am
8-K
01y q0dvv7108zg
2 Mar 22
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
7:06am
8-K
39rrcjmfkqcj
10 Jan 22
Results of Operations and Financial Condition
7:31am
8-K
jguqqn4z3c15yzx
4 Nov 21
Entry into a Material Definitive Agreement
4:21pm
8-K
0oc5i nylz
4 Nov 21
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
7:12am